The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch

Business Of Biotech

We love to hear from our listeners. Send us a message.

This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission in mind -- to help early clinical-stage companies like KSQ Therapeutics prepare for and enter their clinical stage on the best possible footing, and with the best possible clinical partner in the MD Anderson Cancer Center. On this episode of the Business of Biotech, KSQ's Thomas Leitch and Dr. Bock join us to share the story of CTMC's evolution, KSQ's partnership need as it advanced its lead phase 1 TIL therapy for solid tumors, how the partnership unfolded and who's on the hook for what as KSQ begins its clinical journey.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

章

1. The Unique Origin of CTMC (00:00:00)

2. Accelerating Cell Therapy Development With CTMC (00:12:13)

3. Business Alignment and Scientific Collaboration (00:23:14)

4. CTMC's Accelerated Clinical Trial Process (00:30:47)

5. MD Anderson Partnership (00:38:53)

6. Partnership and Future Collaboration Opportunities (00:46:15)